0001193125-22-210648.txt : 20220902 0001193125-22-210648.hdr.sgml : 20220902 20220803082929 ACCESSION NUMBER: 0001193125-22-210648 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 CORRESP 1 filename1.htm CORRESP

X4 PHARMACEUTICALS, INC.

61 North Beacon Street, 4th Floor

Boston, MA 02134

August 3, 2022

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:

Jason Drory

 

RE:

X4 Pharmaceuticals, Inc.

Registration Statement on Form S-3

File No. 333-266410

Acceleration Request

            Requested Date:       August 5, 2022

            Requested Time:      4:00 p.m. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-266410) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Friday, August 5, 2022, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722.

[Signature page follows]

Sincerely,

 

X4 PHARMACEUTICALS, INC.
By:  

/s/ Adam S. Mostafa

  Adam S. Mostafa
  Chief Financial Officer

 

cc:

Paula Ragan, Ph.D., Chief Executive Officer, X4 Pharmaceuticals, Inc.

Derek Meisner, Chief Legal Officer, X4 Pharmaceuticals, Inc.

Daniel I. Goldberg, Cooley LLP

Courtney T. Thorne, Cooley LLP